findmyKOL

Premal Thaker, MD

Enriched profile

Director of the Division of Gynecologic Oncology, David & Lynn Mutch Distinguished Professor of Obstetrics and Gynecology · Washington University School of Medicine in St. Louis

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Saint Louis, MO · Midwest · United StatesSpecialtyGynecologic OncologyFocusOvarian cancer diagnosis and treatment+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2021–2025NIH funding2009–2026

Premal Thaker is Director of the Division of Gynecologic Oncology, David & Lynn Mutch Distinguished Professor of Obstetrics and Gynecology at Washington University School of Medicine in St. Louis. OpenAlex indexes 785 publications with 10,999 citations (h-index 50); ClinicalTrials.gov lists 20 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Gynecologic Oncology profiles in the findmyKOL directory.

Data verified 18 Oct 2026

Overview

Updated 18 Oct 2026

Premal Thaker, MD, is Director of the Division of Gynecologic Oncology, David & Lynn Mutch Distinguished Professor of Obstetrics and Gynecology at Washington University School of Medicine in St. Louis. The public record shows 785 publications with 10,999 citations (h-index 50), centered on Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, BRCA gene mutations in cancer. It also documents an investigator role on 20 registered clinical trials, industry payments reported by 29 companies, 2 NIH-funded awards (2009–2026).

  • Most recent indexed publication: 2026 · Cancer research
  • Top research focus: Ovarian cancer diagnosis and treatment
  • 20 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 29 companies

Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Ovarian / Gynecologic Cancer13 trialsFallopian Tube Neoplasms6 trialsCarcinoma, Ovarian Epithelial4 trialsCarcinoma, Endometrioid4 trialsEndometrial Neoplasms4 trialsUterine Cervical Neoplasms2 trialsAdenocarcinoma, Clear Cell2 trialsCysts1 trialCystadenocarcinoma, Serous1 trialCystadenocarcinoma1 trialAdenocarcinoma, Mucinous1 trialPancreatic Cancer1 trialSarcoma1 trialComa1 trialCarcinosarcoma1 trialUterine Neoplasms1 trialLeiomyoma1 trial

Research focus

OpenAlex concept fingerprint
Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer TreatmentsBRCA gene mutations in cancerPARP inhibition in cancer therapyProtease and Inhibitor Mechanisms

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials—Industry payments15Publications1Zejulageneric · NiraparibClinical trials—Industry payments12Publications1AvutometinibClinical trials1Industry payments—Publications1DefactinibClinical trials1Industry payments—Publications1Lenvimageneric · LenvatinibClinical trials—Industry payments11Publications—Tivdakgeneric · TisotumabClinical trials—Industry payments11Publications—Jemperligeneric · DostarlimabClinical trials—Industry payments10Publications—Korlymgeneric · MifepristoneClinical trials—Industry payments10Publications—Lynparzageneric · OlaparibClinical trials—Industry payments10Publications—Elaheregeneric · Mirvetuximab soravtansineClinical trials—Industry payments6Publications—Amtagvigeneric · LifileucelClinical trials—Industry payments2Publications—Fyarrogeneric · SirolimusClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
GlaxoSmithKline, LLC.Clinical trials—Industry payments39Incyte CorporationClinical trials—Industry payments25Merck Sharp & Dohme LLCClinical trials—Industry payments21Corcept TherapeuticsClinical trials—Industry payments15Seagen Inc.Clinical trials—Industry payments14Eisai Inc.Clinical trials—Industry payments13AstraZeneca Pharmaceuticals LPClinical trials—Industry payments10Washington University School of MedicineClinical trials9Industry payments—Abbvie Inc.Clinical trials—Industry payments8Genmab U.S., Inc.Clinical trials—Industry payments5Novocure Inc.Clinical trials—Industry payments5Caris MPI, Inc.Clinical trials—Industry payments4Merck Sharp & Dohme CorporationClinical trials—Industry payments4ImunonClinical trials3Industry payments—Aadi Bioscience, Inc.Clinical trials—Industry payments2BioNTech SEClinical trials—Industry payments2Clovis Oncology, Inc.Clinical trials—Industry payments2Daiichi Sankyo Inc.Clinical trials—Industry payments2Iovance Biotherapeutics, Inc.Clinical trials—Industry payments2National Cancer Institute (NCI)Clinical trials2Industry payments—Novocure GmbHClinical trials—Industry payments2AstraZeneca UK LimitedClinical trials—Industry payments1Eli Lilly and CompanyClinical trials—Industry payments1Exelixis Inc.Clinical trials—Industry payments1Galvanize Therapeutics, IncClinical trials—Industry payments1Genelux CorporationClinical trials1Industry payments—Genentech, Inc.Clinical trials—Industry payments1GOG FoundationClinical trials1Industry payments—Gynecologic Oncology GroupClinical trials1Industry payments—Hologic, LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
785publications

Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.

10,999citations

Total citations across indexed works.

50h-index

Hirsch index (OpenAlex). i10-index 174.

Clinical & industry

trials, payments and federal funding
20clinical trials

Investigator role on registered studies.

View trials ↓
29companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2009–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 18 Oct 2026

Listed as an investigator on 20 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 18 Oct 2026

29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    66.7%
    Corticosteroid66.7%
    Dexamethasone sodium phosphate95%Dexamethasone5%
    Part D + Part B≥25 patients
  • Nervous system

    15%
    Gabapentinoids3.8%
    Gabapentin72%Pregabalin28%
    Part D<11 patients
    Opioid Agonist3.3%
    Oxycodone Hcl63%Oxycodone-Acetaminophen37%
    Part D<11 patients

    + 5 more classes in this area

  • Metabolism & gastrointestinal

    3.4%
    Serotonin-3 Receptor Antagonist3.4%
    Ondansetron Hcl100%
    Part D≥27 patients
All 11 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)3.1% facility · 96.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 18 Oct 2026

2 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:

Congress activity

Updated 18 Oct 2026

80 congress contributions (2006–2026) across AACR, ADA, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

Publications

Updated 18 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 18 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

David Gardner Mutch372Andrea R. Hagemann322Carolyn Kay McCourt286Lindsay M. Kuroki284Matthew A. Powell271Katherine Cynthia Fuh225Mary Margaret Mullen208Dineo Khabele196Peinan Zhao142Elena Lomonosova140Matthew A. Powell116Hollie M Noia104Ian S. Hagemann98Leslie Stewart Massad97Elizabeth C. Stock91Gary J. Patti84Molly M. Greenwade80Kevin Cho80Leah P. Shriver80Emilee N. Kotnik79Kathleen N. Moore78Mark C. Valentine78Amanda J. Compadre76Nima Mosammaparast76Bisiayo Fashemi76Lulu Sun74Whitney R. Grither73Shariska Petersen Harrington70Daniel Wilke70Violeta Serra70Lillian N. van Biljon69Isaac Cooper68Emily Graham68Alba Llop‐Guevara68Andrea Herencia-Ropero68Angela M. Schab67Gregory D. Longmore67Carol A Aghajanian62Anil K. Sood56Els Van Nieuwenhuysen47

Online presence

Updated 18 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    obgyn.wustl.edu/gynecologic-oncology-chief-dr-premal-thaker-joins-fpp-board-of-directors

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →obgyn.wustl.edu ↗
  • Other

    ovarcome.transistor.fm/episodes/transforming-treatment-in-ovarian-cancer-breakthroughs-offering-hope

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ovarcome.transistor.fm ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 18 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.